This listing of claims will replace all prior versions of claims in the application.

Claims 1-27. (cancelled)

Claim 28. (new) A transdermal therapeutic system comprising a drug-containing adhesive matrix, in which the drug is Rotigotine ((-)-5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl)amino]-1-naphthol) or a prodrug of Rotigotine,

wherein the adhesive matrix contains a hot-meltable adhesive, the hot-meltable adhesive consisting of one adhesive or a mixture of different adhesives or of a mixture of an adhesive and a softener and exhibiting at 160°C a dynamic viscosity of not more than 100 Pa.s.

Claim 29. (new) The transdermal therapeutic system of claim 28 wherein Rotigotine or prodrug thereof is dispersed or partly or completely dissolved in said hot-meltable adhesive.

Claim 30. (new) The transdermal therapeutic system of claim 28 wherein the drug-containing adhesive matrix is produced by metering the Rotigotine or prodrug thereof into the solvent-free melt of the adhesive matrix at a temperature of between 120°C and 160°C.

Claim 31. (new) The transdermal therapeutic system of claim 28 wherein the hot-meltable adhesive consists of a mixture of an amine-resistant silicone adhesive and at least one suitable softener.

Claim 32. (new) The transdermal therapeutic system of claim 31 wherein the softener is an organic wax.

Claim 33. (new) The transdermal therapeutic system of claim 31 wherein the softener is ceresine or ozokerite.

Claim 34. (new) The transdermal therapeutic system of claim 28 wherein the proportion of Rotigotine or prodrug thereof in the adhesive layer is 4 to 40 weight%.

Claim 35. (new) The transdermal therapeutic system of claim 28 wherein the proportion of Rotigotine or prodrug thereof in the adhesive layer is 9 to 30 weight%.

Claim 36. (new) The transdermal therapeutic system of claim 28 wherein the proportion of Rotigotine or prodrug thereof in the adhesive layer is 20 to 40 weight%.

Claim 37. (new) The transdermal therapeutic system of claim 28 wherein Rotigotine or prodrug thereof is present as the active ingredient in form of a base.

Claim 38. (new) The transdermal therapeutic system of claim 28 wherein the drug-containing adhesive matrix additionally contains an internal-phase component selected from the group of:

(a) hydrophilic or amphiphilic polymers
(b) hydrophilic or amphiphilic copolymers
(c) mixtures of (a) and/or (b) with pharmaceutically acceptable softeners
(d) condensates from glycerin and fatty acids or polyols
(e) suitable mixtures of the components (a)-(d).

Claim 39. (new) The transdermal therapeutic system of claim 38 wherein the internal-phase component is selected from the group of:

polysaccharides, substituted polysaccharides, polyethylene oxides, polyvinyl acetates, polyvinyl pyrrolidones, copolymers from polyvinyl pyrrolidone and (poly)vinyl acetate, polyethylene glycol, polypropylene glycol, copolymers from ethylene and vinyl acetate, glycerin-fatty acid esters as well as mixtures of polyvinyl alcohol with glycerin.

Claim 40. (new) The transdermal therapeutic system of claim 28 wherein the adhesive matrix comprises:

(a) 50-99 weight% of said hot-meltable adhesive

(b) 4-40 weight% Rotigotine

(c) 0-40 weight% of an internal-phase component

(d) 0-10 weight% other adjuvants.

Claim 41. (new) The transdermal therapeutic system of claim 28 wherein the hot-meltable adhesive is selected from among:

(a1) an EVA adhesive

(a2) an SxS adhesive, or

(a3) a mixture of

(i) 70-99 weight% of an amine-resistant silicone adhesive

(ii) 1-30 weight% of a suitable softener.

Claim 42. (new) The transdermal therapeutic system of claim 28 wherein the system comprises Rotigotine.

Claim 43. (new) The transdermal therapeutic system of claim 28 wherein the system comprises a prodrug of Rotigotine.

Claim 44. (new) The transdermal therapeutic system of claim 43 wherein the prodrug is an ester or carbamate of Rotigotine.

Claim 45. (new) A transdermal therapeutic system for administration of Rotigotine, comprising:

a layer that comprises Rotigotine or a prodrug of Rotigotine,

wherein the layer

(a) contains Rotigotine or prodrug thereof in a percentile proportion of at least 20 weight%,

(b) has a Rotigotine or prodrug thereof content of at least 2.0 mg/cm^2, and

(c) optionally contains an organic wax and/or internal-phase component in an amount sufficient to retard the release of the active substance.

Claim 46. (new) The transdermal therapeutic system of claim 45 wherein Rotigotine or prodrug thereof is transported through the skin at a steady-state flux rate of 100-500 μg per hour over a period of at least 5 days.

Claim 47. (new) The transdermal therapeutic system of claim 45 wherein Rotigotine or prodrug thereof is transported through the human skin at a flux rate of 100-500 μg per hour over a period of at least 7 days.

Claim 48. (new) The transdermal therapeutic system of claim 45 wherein the system induces in the patient an average plasma concentration of 0.4 to 2 ng/ml Rotigotine for a period of at least 5 days.

Claim 49. (new) The transdermal therapeutic system of claim 45 wherein the system comprises Rotigotine.

Claim 50. (new) The transdermal therapeutic system of claim 45 wherein the system comprises a prodrug of Rotigotine.

Claim 51. (new) The transdermal therapeutic system of claim 50 wherein the prodrug is an ester or carbamate of Rotigotine.

Claim 52. (new) A method for producing a transdermal therapeutic system that encompasses an adhesive matrix comprises Rotigotine or a prodrug of Rotigotine as the drug, the method comprising:

prior to lamination components of the adhesive matrix are melted and homogenized, solvent-free, at temperatures of between 70°C and 200°C.

Claim 53. (new) The method of claim 52 wherein components of the adhesive matrix are melted and homogenized in an extruder.

Claim 54. (new) The method of claim 52 wherein the hot-melting process takes place at temperatures between 120°C and 160°C.

Claim 55. (new) The method of claim 52 wherein Rotigotine or prodrug thereof is introduced, in the adhesive matrix melt, in its solid state.

Claim 56. (new) The method of claim 52 wherein the adhesive matrix, produced by the hot-melting process, contains Rotigotine or prodrug thereof at a purity level of at least 98% as measured by HPLC at 220 nm and 272 nm.

Claim 57. (new) The method of claim 52 wherein the system comprises Rotigotine.

Claim 58. (new) The method of claim 52 wherein the system comprises a prodrug of Rotigotine.

Claim 59. (new) The method of claim 58 wherein the prodrug is an ester or carbamate of Rotigotine.